Equities analysts expect VBI Vaccines Inc (NASDAQ:VBIV) to post $360,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VBI Vaccines’ earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $210,000.00. VBI Vaccines reported sales of $650,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 44.6%. The company is expected to issue its next earnings results on Wednesday, November 4th.
According to Zacks, analysts expect that VBI Vaccines will report full year sales of $1.42 million for the current financial year, with estimates ranging from $1.13 million to $1.70 million. For the next financial year, analysts anticipate that the firm will post sales of $5.26 million, with estimates ranging from $4.10 million to $6.42 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Friday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.86 million. VBI Vaccines had a negative net margin of 2,467.47% and a negative return on equity of 46.47%.
A number of hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. raised its holdings in shares of VBI Vaccines by 64.8% in the first quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 10,300 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of VBI Vaccines in the second quarter valued at approximately $30,000. Prudential Financial Inc. acquired a new stake in shares of VBI Vaccines in the second quarter valued at approximately $31,000. Royal Bank of Canada raised its holdings in shares of VBI Vaccines by 832.1% in the first quarter. Royal Bank of Canada now owns 35,437 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 31,635 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of VBI Vaccines in the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 42.59% of the company’s stock.
Shares of NASDAQ:VBIV traded down $0.12 during mid-day trading on Monday, reaching $2.96. The stock had a trading volume of 6,925,462 shares, compared to its average volume of 10,427,736. The firm has a market cap of $684.35 million, a PE ratio of -11.38 and a beta of 1.79. The firm has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $2.62. The company has a current ratio of 5.86, a quick ratio of 5.77 and a debt-to-equity ratio of 0.13. VBI Vaccines has a twelve month low of $0.47 and a twelve month high of $6.93.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Further Reading: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.